Favorable Response to Immunosuppressive Therapy in Severe Aplastic Anemia With Trisomy 8 and BCOR Mutation: Sustained Hematologic Response Despite Evolving Mutational Profile-A Case Report.

Mengzhu Shen, Yan Wei, Bo Shao, Cao Qin, Xiaofei Jia, Hao Jiang, Jinsong Jia

Abstract read

In one paragraph

Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mengzhu ShenPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology Peking University Beijing China.ORCID https://orcid.org/0000-0002-8640-7017

Yan WeiPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology Peking University Beijing China.

Bo ShaoBeijing Qinghe Hospital Beijing China.

Cao QinBeijing Qinghe Hospital Beijing China.

Xiaofei JiaBeijing Qinghe Hospital Beijing China.

Hao JiangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology Peking University Beijing China.

Jinsong JiaPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology Peking University Beijing China.ORCID https://orcid.org/0000-0003-1009-8024

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe aplastic anemia (SAA) is a serious medical condition that is characterized by its abrupt onset, rapid progression of the disease, and alarmingly high mortality rate, making it a significant concern in the field of hematology. Intensive immunosuppressive therapy (IST) is one of the primary therapeutic options; however, some SAA patients do not respond to initial IST treatment. For these patients, salvage treatment remains a significant challenge. Consequently, predicting the efficacy of IST for SAA at initial diagnosis and developing the optimal curative regimen could potentially enhance treatment outcomes. The concurrent presence of trisomy 8 and a BCL6 corepressor (

Indexed as

BCOR mutationcase reportintensive immunosuppressive therapysevere aplastic anemiatrisomy 8

Identifiers

PMID42592205

DOI10.1002/ccr3.73321

PMCPMC13463310

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.